BLAINJECTIONINJECTABLE6 Generics Approved
Approved
May 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZOMACTON (somatropin) by Ferring Pharmaceuticals is cells. Approved for short stature associated with turner syndrome, idiopathic short stature (iss), height standard deviation score (hsds) ≤-2. First approved in 1995.
Drug data last refreshed 15h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZOMACTON is a recombinant human growth hormone (somatropin) administered by injection for treating growth hormone deficiency and related growth disorders. It replaces or supplements endogenous growth hormone to promote linear growth, muscle development, and metabolic function in pediatric and adult populations.
$0.068BPart D
LOE ApproachingDeclining
LOE-stage product with modest Part D footprint (68 claims, $68K spending in 2023) suggests a stabilized but shrinking commercial team focused on retention rather than growth.
Mechanism of Action
cells. This interaction results in intracellular signal transduction and subsequent induction of transcription and translation of GH-dependent proteins including IGF-1, IGF BP-3 and acid-labile subunit. Somatropin has direct tissue and metabolic effects or effects mediated indirectly by IGF-1,…
Worked on ZOMACTON at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.